Brammer Jonathan E, Khouri Issa, Marin David, Ledesma Celina, Rondon Gabriela, Ciurea Stefan O, Nieto Yago, Champlin Richard E, Hosing Chitra, Kebriaei Partow
a Department of Stem Cell Transplantation and Cellular Therapy , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Leuk Lymphoma. 2017 Feb;58(2):366-371. doi: 10.1080/10428194.2016.1193860. Epub 2016 Jun 27.
Lymphoblastic lymphoma (LBL) is an aggressive lymphoma pathologically similar to lymphoblastic leukemia, but primarily presents with nodal or extra-medullary involvement. The aim of this study is to describe outcomes of patients undergoing stem cell transplantation (SCT) for LBL compared to historical data. Thirty-nine patients, of which 54% lacked complete remission (CR), received SCT for LBL between 1990 and 2015; 31 allogeneic and eight autologous. Overall survival (OS) and progression free survival (PFS) at three years for the entire cohort was 41%, the cumulative incidence (CI) of non-relapse mortality (NRM) was 18% at one year, and CI relapse mortality was 28% at one-year and 36% at three years; results similar to historical reports. On multivariate analysis, the use of total-body irradiation (TBI) based conditioning and transplantation in CR were independently predictive of OS and PFS. For patients requiring SCT for LBL, CR and TBI-based conditioning prior to allogeneic SCT may provide improved disease control.
淋巴母细胞淋巴瘤(LBL)是一种侵袭性淋巴瘤,病理上与淋巴母细胞白血病相似,但主要表现为淋巴结或髓外受累。本研究的目的是描述与历史数据相比,接受干细胞移植(SCT)治疗LBL的患者的预后。1990年至2015年间,39例LBL患者接受了SCT,其中54%未达到完全缓解(CR);31例接受异基因移植,8例接受自体移植。整个队列三年的总生存率(OS)和无进展生存率(PFS)为41%,一年时非复发死亡率(NRM)的累积发生率(CI)为18%,一年时CI复发死亡率为28%,三年时为36%;结果与历史报告相似。多因素分析显示,基于全身照射(TBI)的预处理和在CR时进行移植可独立预测OS和PFS。对于需要SCT治疗LBL的患者,CR以及异基因SCT前基于TBI的预处理可能会改善疾病控制。